Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria

Thomas P. Buters; Willemijn W.A.C. van der Velden; Ismahaan Abdisalaam; Maurits S. van Maaren; Martijn B.A. van Doorn

doi:10.1016/j.jaip.2021.04.034

Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria

Thomas P. Buters, Willemijn W.A.C. van der Velden, Ismahaan Abdisalaam, Maurits S. van Maaren, Martijn B.A. van Doorn^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	3227-3229
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	9
Issue number	8
DOIs	https://doi.org/10.1016/j.jaip.2021.04.034
Publication status	Published - Aug 2021

Access to Document

10.1016/j.jaip.2021.04.034

Cite this

@article{bfaf8d8076334065977afc30e641f547,

title = "Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria",

author = "Buters, {Thomas P.} and {van der Velden}, {Willemijn W.A.C.} and Ismahaan Abdisalaam and {van Maaren}, {Maurits S.} and {van Doorn}, {Martijn B.A.}",

note = "Funding Information: Conflicts of interest: Dr van Doorn reports personal fees from Leopharma, grants and personal fees from Novartis, personal fees from Abbvie, personal fees from BMS, personal fees from Celgene, personal fees from Lilly, personal fees from MSD, personal fees from Pfizer, personal fees from Sanofi-Genzyme, and personal fees from Janssen Cilag, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2021",

month = aug,

doi = "10.1016/j.jaip.2021.04.034",

language = "English",

volume = "9",

pages = "3227--3229",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "8",

}

Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria. / Buters, Thomas P.; van der Velden, Willemijn W.A.C.; Abdisalaam, Ismahaan ; van Maaren, Maurits S.; van Doorn, Martijn B.A.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, No. 8, 08.2021, p. 3227-3229.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria

AU - Buters, Thomas P.

AU - van der Velden, Willemijn W.A.C.

AU - Abdisalaam, Ismahaan

AU - van Maaren, Maurits S.

AU - van Doorn, Martijn B.A.

N1 - Funding Information: Conflicts of interest: Dr van Doorn reports personal fees from Leopharma, grants and personal fees from Novartis, personal fees from Abbvie, personal fees from BMS, personal fees from Celgene, personal fees from Lilly, personal fees from MSD, personal fees from Pfizer, personal fees from Sanofi-Genzyme, and personal fees from Janssen Cilag, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85105531713&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2021.04.034

DO - 10.1016/j.jaip.2021.04.034

M3 - Article

C2 - 33915307

AN - SCOPUS:85105531713

VL - 9

SP - 3227

EP - 3229

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 8

ER -

Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria

Access to Document

Other files and links

Cite this